Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Eptifibatide
Drug ID BADD_D00792
Description Synthetic cyclic hexapeptide that binds to platelet receptor glycoprotein and inhibits platelet aggregation. Derived from venom of the Southeastern pygmy rattlesnake (Sistrurus miliarus barbouri), eptifibatide is a cyclic heptapeptide that belongs to the class of arginin-glycin-aspartat-mimetics.
Indications and Usage For treatment of myocardial infarction and acute coronary syndrome.
Marketing Status approved; investigational
ATC Code B01AC16
DrugBank ID DB00063
KEGG ID D06888
MeSH ID D000077542
PubChem ID 448812
TTD Drug ID D09ZIO
NDC Product Code 36974-0068; 52958-001; 25021-409; 52958-040; 67457-630; 70860-303; 14403-0007; 67457-631; 70860-305; 72078-027; 0338-9558; 70436-026; 52958-402; 70436-162; 41524-0002; 55150-220; 67457-629; 70121-1002; 72078-025; 32861-0002; 16729-259; 55150-218; 55150-219; 70121-1003; 70436-027; 70436-163; 52958-128; 16729-260; 72078-026; 25021-408
UNII NA8320J834
Synonyms Eptifibatide | Epifibratide | Epifibatide | 7H-Pyrrolo(2,1-g)(1,2,5,8,11,14,17,20)dithiahexaazacyclotricosine-17-acetic acid, 3-(aminocarbonyl)-11-(4-((aminoiminomethyl)amino)butyl)docosahydro-20-(1H-indol-3-ylmethyl)-1,9,12,15,18,21-hexaoxo-, (3R,11S,17S,20S,25aS)- | Integrilin | Integrelin
Chemical Information
Molecular Formula C35H49N11O9S2
CAS Registry Number 188627-80-7
SMILES C1CC2C(=O)NC(CSSCCC(=O)NC(C(=O)NCC(=O)NC(C(=O)NC(C(=O)N2C1)CC3=CNC4=CC=CC=C43)CC (=O)O)CCCCN=C(N)N)C(=O)N
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal pain07.01.05.002--
Acute myocardial infarction24.04.04.001; 02.02.02.0010.000082%Not Available
Anaphylactic shock24.06.02.004; 10.01.07.002--Not Available
Angioplasty25.03.01.005--Not Available
Atrial fibrillation02.03.03.002--
Atrioventricular block02.03.01.002--Not Available
Body temperature increased13.15.01.001--Not Available
Cardiac arrest02.03.04.0010.000206%
Cardiac failure02.05.01.001--
Cardiac failure congestive02.05.01.002--Not Available
Cerebral haemorrhage24.07.04.001; 17.08.01.003--Not Available
Cerebral infarction24.04.06.002; 17.08.01.004--Not Available
Cerebral ischaemia24.04.06.003; 17.08.01.005--
Cerebrovascular accident17.08.01.007; 24.03.05.001--
Chest pain22.12.02.003; 08.01.08.002; 02.02.02.0110.000082%Not Available
Coronary artery bypass25.03.03.003--Not Available
Coronary artery disease24.04.04.006; 02.02.01.001--Not Available
Coronary artery occlusion12.02.01.036; 24.04.04.013; 02.02.01.006--Not Available
Dermatitis23.03.04.002--Not Available
Disseminated intravascular coagulation24.01.01.010; 01.01.02.0020.000082%
Drug ineffective08.06.01.0060.000502%Not Available
Dyspepsia07.01.02.001--
Dyspnoea02.11.05.003; 22.02.01.004--
Epistaxis24.07.01.005; 22.04.03.0010.000123%
Gastrointestinal haemorrhage24.07.02.009; 07.12.02.0010.000321%Not Available
Gastrointestinal pain07.01.05.005--
Haemarthrosis24.07.01.046; 15.01.01.004; 12.04.03.0010.000082%Not Available
Haematemesis24.07.02.011; 07.12.02.002--Not Available
Haematocrit decreased13.01.05.001--Not Available
Haematoma24.07.01.0010.000082%
The 1th Page    1 2 3    Next   Last    Total 3 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene